Citadel Advisors
LKFT

Citadel Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Citadel Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,100
Closed -$303K – 14122
2026
Q1 		$303K Sell
10,100
-8,700
-46% -$288K ﹤0.01% 10452
2025
Q4 		$615K Buy
18,800
+7,100
+61% +$229K ﹤0.01% 8536
2025
Q3 		$405K Sell
11,700
-28,700
-71% -$918K ﹤0.01% 9636
2025
Q2 		$1.13M Buy
40,400
+22,000
+120% +$590K ﹤0.01% 6819
2025
Q1 		$462K Buy
18,400
+15,000
+441% +$379K ﹤0.01% 8645
2024
Q4 		$93.5K Sell
3,400
-11,200
-77% -$312K ﹤0.01% 11576
2024
Q3 		$420K Buy
14,600
+7,200
+97% +$196K ﹤0.01% 8635
2024
Q2 		$183K Buy
7,400
+600
+9% +$17K ﹤0.01% 10063
2024
Q1 		$219K Sell
6,800
-1,600
-19% -$59.5K ﹤0.01% 10131
2023
Q4 		$341K Buy
8,400
+3,400
+68% +$125K ﹤0.01% 8900
2023
Q3 		$173K Buy
5,000
+2,000
+67% +$77.9K ﹤0.01% 10146
2023
Q2 		$122K Buy
3,000
+200
+7% +$8.16K ﹤0.01% 10629
2023
Q1 		$108K Sell
2,800
-50,800
-95% -$2.09M ﹤0.01% 11143
2022
Q4 		$2.38M Buy
53,600
+33,600
+168% +$1.41M ﹤0.01% 5149
2022
Q3 		$853K Sell
20,000
-17,300
-46% -$886K ﹤0.01% 7338
2022
Q2 		$2.08M Buy
37,300
+16,700
+81% +$990K ﹤0.01% 5466
2022
Q1 		$1.28M Buy
20,600
+8,500
+70% +$520K ﹤0.01% 7132
2021
Q4 		$667K Sell
12,100
-24,900
-67% -$1.3M ﹤0.01% 8951
2021
Q3 		$1.95M Buy
37,000
+16,200
+78% +$962K ﹤0.01% 6420
2021
Q2 		$1.43M Sell
20,800
-14,100
-40% -$1.08M ﹤0.01% 7423
2021
Q1 		$2.69M Buy
34,900
+9,600
+38% +$884K ﹤0.01% 5707
2020
Q4 		$2.5M Buy
25,300
+5,100
+25% +$624K ﹤0.01% 4889
2020
Q3 		$2.87M Sell
20,200
-7,000
-26% -$1.17M ﹤0.01% 4056
2020
Q2 		$5.37M Buy
27,200
+6,800
+33% +$1.41M ﹤0.01% 2996
2020
Q1 		$4M Buy
20,400
+13,800
+209% +$2.97M ﹤0.01% 3032
2019
Q4 		$1.36M Sell
6,600
-7,100
-52% -$1.31M ﹤0.01% 5032
2019
Q3 		$2.09M Sell
13,700
-5,900
-30% -$967K ﹤0.01% 4424
2019
Q2 		$2.53M Sell
19,600
-12,800
-40% -$1.52M ﹤0.01% 4127
2019
Q1 		$3.82M Buy
+32,400
New +$3.27M ﹤0.01% 3379
2018
Q4 		– Sell
-6,800
Closed -$765K – 9351
2018
Q3 		$765K Buy
+6,800
New +$718K ﹤0.01% 5999

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Citadel Advisors's LKFT Position: Q2 2026 in Review

Citadel Advisors reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 29% in Q2 2026, selling an estimated $1.02M and leaving 88,343 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #5936.

Citadel Advisors first reported a position in LKFT in Q2 2015 and has held it in 39 quarters since. The position peaked at $31.2M in Q2 2021. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

  • Citadel Advisors held 88,343 shares of Lakefront Biotherapeutics American Depositary Shares worth $2.65M as of Q2 2026.
  • Citadel Advisors sold 36,085 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $1.02M.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5936 holding.
  • Citadel Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 39 quarters since.
  • Citadel Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $31.2M in Q2 2021.
  • 76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.